Acurx Pharmaceuticals Inc (ACXP)

[gfp927z]

The 1 month durability data looks great though, so next will be the 94 day data in Jan. Looks like Ibexa is performing exactly as hoped, while Vancomycin is moving toward it's historically poor recurrence rate. We know Ibeza spares the healthy microbiome, while Vanc destroys it, so over time the differential should expand even more in Ibeza's favor. The excellent 1 month durability data (100%) de-risks the stock and makes it a far safer long term buy / hold imo.

Today's 'sell on the news' activity was on fairly high volume, so some of the selling might be related to the warrant shares (?) If so, then Acurx gets some additional non-dilutive cash coming in. In the Nov 14 conference call, CEO Luci said that up to $15 mil could potentially be obtained via the exercise of the existing warrants.

Anyway, next up will be the 94 day durability data (Jan), and the microbiome data. So here's hoping for continued success :o)




---